RT Journal Article
SR Electronic
T1 A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 379
OP 384
DO 10.21873/anticanres.14786
VO 41
IS 1
A1 DIRK RADES
A1 JASPAR WITTELER
A1 STEVEN E. SCHILD
A1 PETER TRILLENBERG
A1 MATTEO M. BONSANTO
A1 JAN LEPPERT
YR 2021
UL http://ar.iiarjournals.org/content/41/1/379.abstract
AB Background/Aim: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors. Patients and Methods: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score. Results: All factors were significantly associated with survival. For each factor, 0 points (less favorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001). Conclusion: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization.